Company intelligence
Granite Bio
Biotechnology Research
Basel, CH
27 employees
Founded 2021
5 public signals
About Granite Bio
Targeting fundamentals of inflammation, autoimmunity and fibrosis
Verified activity
Signals from Granite Bio
5 published signals
Research & Knowledge
Granite Bio is developing a new extracellular matrix modification technology.
Reported by Dominik Hartl, MD
Strategy & Corporate Development
Granite Bio is developing a new product line for the immune-mediated rheumatoid arthritis (RA) market.
Reported by Dominik Hartl, MD
Research & Knowledge
Granite Bio's Dominik Hartl, MD presented a paper on interleukin-33 and its receptor multifaceted activity at the 2026 Annual Meeting of the American Society of Clinical Oncology
Reported by Dominik Hartl, MD
Presence & Recognition
Granite Bio employee Dominik Hartl has been featured in a LinkedIn post.
Reported by Dominik Hartl, MD
Research & Knowledge
Granite Bio resolved IBD risk mapping using cell-type analyses.
Reported by Dominik Hartl, MD